Infectious disease
The companies also plan to develop the candidate for the treatment of other potential future viral diseases.
The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.
As the U.S. reports surges in COVID-19 infections despite increased enrollment in vaccines, news continues to break about therapies, vaccines, and the risks involved with the new vaccines. Here’s a look.
The vaccine distribution has been paused in the country because of six or seven cases of rare blood clots.
It has been reported that Johnson & Johnson contacted Pfizer, Moderna, and AstraZeneca about investigating the clots and to “speak with one voice about safety.” However, both Pfizer and Modera declined, indicating that their vaccines were not associated with blood clots.
The reason for the request was the monotherapy antibody therapy is less effective against the COVID-19 variants, such as have risen from the U.K., South Africa and Brazil, as well as the growing B.1.427/B.1.429 California variant.
Although the data is not there, Pfizer’s chief executive officer, Albert Bourla, recently said he thought people will “likely” need a booster dose of a vaccine within 12 months of getting fully vaccinated. It’s possible, he also said, they will need to be vaccinated annually.
Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
The U.S. FDA’s Advisory Committee on Immunization Practices (ACIP) met yesterday to make a recommendation on the current pause of the Johnson & Johnson COVID-19 vaccine.
The U.S. CDC said up to 5,800 people who have been fully vaccinated against coronavirus disease 2019 (COVID-19) have been infected by the novel coronavirus following vaccination.
PRESS RELEASES